Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 14/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.46 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | PAK3 | O75914 | 1/20 | 0.46 |
| ▸ | PAK4 | O96013 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.46 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.46 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | WEE1 | P30291 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035477 | 0.87 | TNK2 (0.55) | TNK2KCNH2FGFR1CDK4CCNA2 | |
| SCHEMBL15035370 | 0.80 | TNK2 (0.52) | TNK2KCNH2FGFR1CDK4CCNA2 | |
| SCHEMBL15041805 | 0.79 | CDK4 (0.57) | FGFR1CDK4CCNA2FGFR2FGFR4 | |
| SCHEMBL15035351 | 0.79 | CDK2 (0.45) | TNK2FGFR1CDK4CCNA2FGFR2 | |
| SCHEMBL15035380 | 0.78 | CDK4 (0.55) | FGFR1CDK4CCNA2FGFR2FGFR4 | |
| SCHEMBL15035413 | 0.78 | CDK4 (0.58) | FGFR1CDK4CCNA2FGFR2FGFR4 | |
| SCHEMBL15035548 | 0.76 | RIPK2 (0.43) | TNK2FGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL15034848 | 0.76 | TNK2 (0.60) | TNK2PAK3PAK4LIMK1LIMK2 | |
| SCHEMBL29785351 | 0.75 | TNK2 (0.66) | TNK2EGFR | |
| SCHEMBL20674137 | 0.75 | TNK2 (0.66) | TNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | TNK2 7/4885KCNH2 4768/4885FGFR1 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.